SCIENCE AND INNOVATION FOR A BETTER LIFE
Cilian is an innovative biotechnology company with 900 m2 of laboratory space, a pilot-scale 900 l bioreactor and 30 employees. It utilises the unique capabilities of ciliates, a class of eukaryotic microorganisms, for the industrial production of therapeutic proteins.
The company's R&D team has more than 20 years of experience in applied research and development of its ciliate-based expression system.
Worldwide, Cilian is the only biotech company using a system such as CIBEX with corporate partners. CIBEX is ready to produce a wide range of biopharmaceutical compounds, in particular therapeutic enzymes, monoclonal antibodies with improved anticancer activity as well as viral and protozoal vaccines.
Therapeutic targets include the treatment of digestive disorders, cancer susceptible to immunotherapy with monoclonal antibodies, and viral infectious diseases, to name just a few.
A DEDICATED TEAM IS OUR FOUNDATION
An experienced and ambitious team of entrepreneurial scientists and technicians forms the foundation of the Research & Development (R&D) team.
Within the framework of cooperations, feasibility studies and research contracts, this team has already successfully demonstrated the performance of the technology platform on several occasions.
OUR DIVISIONS FOR THE PRODUCTION OF BIOPHARMACEUTICS
An innovative expression platform for the highly productive fabrication of protein-based biopharmaceuticals
A sub-unit vaccine for the treatment of seasonal and pandemic flu
A new active ingredient for pancreas insufficiency
Production of monoclonal antibodies based on the CIBEX expression system